Cytokine Responses to Intraventricular Injection of Interleukin 2 into Patients with Leptomeningeal Carcinomatosis: Rapid Induction of Tumor Necrosis Factor a, Interleukin 10, Interleukin 6, -Interferon, and Soluble Interleukin 2 Receptor (Mr 55,000 Protein)

Cancer Research

Volumn 52, Issue 5, 1992, Pages 1123-1128

  Grimm, E A ^a,b   Steuer, M ^b   Blacklock, J B ^b  

^a Departments of Tumor Biology   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRAIN METASTASIS; CARCINOMATOSIS; CELL MIGRATION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; DRUG EFFECT; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LEPTOMENINX; LYMPHOCYTE; MALE; NEUTROPHIL; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; FEMALE; HUMAN; INJECTIONS, INTRAVENTRICULAR; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTE COUNT; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGE; RECEPTORS, INTERLEUKIN-2; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0026560505     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Grimm, E. A., Ramsey, K., Mazumder, A., Wilson, D. J., Djeu, J., and Rosenberg, S. A. Lymphokine activated killer cell phenomenon. II. The precursor phenotype is serologically distinct from peripheral T-lymphocyte memory CTL and NK-cells. J. Exp. Med., 158:1356-1361,1983.
2. Grimm, E. A., Robb, R. J., Roth, J. A., Neckers, L. M., Lackman, L., Wilson, D. J., and Rosenberg, S. A. The lymphokine-activated-killer cell phenomenon. III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK. J. Exp. Med., 132:2190-2198,1984.
3. Economou, J. S., McBride, W. H., Essner, R., Roades, K., Golub, S., Holmes, E. C., and Morton, D. L. Tumor necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology, 67:514-519,1989.
4. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. The lymphokine activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155:1823-1841,1982.
5. Grimm, E. A., Owen-Schaub, L. B., Loudin, W. G., and Yagita, M. lymphokine-activated killer cells. Induction and function. Ann. NY Acad. Sci., 532:380-386,1988.
6. Danis, V. A., Kulesz, A. J., Nelson, D. S., and Brooks, P. M. Cytokine regulation of human monocyte interleukin-1 (IL-1) production in vitro. Enhancement of IL-1 production by interferon (IFN) gamma, tumor necrosis factor-±, IL-2, and IL-1, and inhibition by 1FN-±. Clin. Exp. Immunol., 80: 435-443,1990.
7. Tratrakovsky, B., Finnegan, A., Muegge, K., Brody, D. T., Kovacs, E. J., Smith, Berzofsky, J. A., Young, H. A., and Durum, S. K. IL-1 is an autocrine growth factor for T-cell clones. J. Immunol., 141: 3863-3867,1988.
8. McBride, W. H., Economou, J. S., Nayersina, R., Comoro, S., and Essner, R. Influences of interleukins 2 and 4 on tumor necrosis factor production by murine mononuclear phagocytes. Cancer Res., 50:2949-2952,1990.
9. Owen-Schaub, L. B., De Mars, M., Murphy, E. C., Jr., and Grimm, E. A. IL-2 dose regulates TNF-α mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cell. Immunol., 132:193-200,1991.
10. Dupere, S., Obiri, N., Lackey, A., Emma, D., Yannelli, J., Orr, D., Birch, R., and O'Conner, E. T. Patterns of cytokines released by peripheral blood leucocytes of normal donors and cancer patients during interleukin-2 activation in vitro. J. Biol. Response Modifiers, 9:140-148,1990.
11. Mier, J. W., Vachino, G., Klempner, M. S., Aronson, F. R., Noring, R., Smith, S., Brandon, E. P., Laird, W., and Atkins, M. B. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood, 78:1933-1944,1991.
12. Hofman, F. M., Hinton, D. R., Johnson, K., and Merrill, J. E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med., 170:607-612,1989.
13. Hofman, F. M., von-Hanwehr, R. I., Dinarello, C. A., Mizel, S. B., Hinton, D., and Merrill, J. E. Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain. J. Immunol., 136:3239-3245, 1986.
14. Ramillo, O., Mustafa, M. N., Porter, J., Saez-Llorens, X., Mertsola, J., Olsen, K. D., Luby, J. P., Beutler, B., and McCracken, G. H., Jr. Detection of interleukin 1/9 but not tumor necrosis factor-a in cerebrospinal fluid of children with aseptic meningitis. Am. J. Dis. Child, 144:349-352,1990.
15. Righi, M., Mori, L., De-Libero, G., Sironi, M., Biondi, A., Mantovani, A., Donini, S. D., and Ricciardi-Castagnoli, P. Monokine production by microglial cell clones. Eur. J. Immunol., 19:1443-1448, 1989.
16. Selmq, K. J., Farooq, M., Norton, W. T., Raine, C. S., and Brosnan, C. F. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol., 144:129-135,1990.
17. Chung, I. Y., and Benveniste, E. N. Tumor necrosis factor-a production by astrocytes. Induction by lipopolysaccharide, IFN-γ, and IL-10. J. Immunol., 144:2999-3007,1990.
18. Clark, J. W., Smith, J. W., II, Steis, R. G., Urba, W. J., Crum, E., Miller, R., McKnight, J., Beman, J., Stevenson, H. C., Creekmore, S., Stewart, M., Conlon, K., Sznol, M., Kremers, P., Cohen, P., and Longo, D. L. Interleukin-2 and lymphokine-activated killer cell therapy: analysis of a bolus and a continuous injection of interleukin 2 regimen. Cancer Res., 50:7343-7350, 1990.
19. Sculier, J. P., Body, J. J., Donnadieu, N., Nejai, S., Gilbert, F., Raymakers, N., and Paesmans, M. Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. Cancer Chemother. Pharmacol., 26:355-358,1990.
20. Sarna, G. P., Figlin, R. A., Pertcheck, M., Altrock, B., and Knujjian, S. A. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. J. Biol. Response Modifiers, 8:16-24,1989.
21. Parkinson, D. R., Fisher, R. I., Rayner, A. A., Paietta, E., Margolin, K. A., Weiss, G. R., Mier, J. W., Sznol, M., Gaynor, E. R., and Bar, M. H. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated-killer cells: Phase II experience with hybrid bolus and continuous infusion interleukin-2 regimen. J. Clin. Oncol., 8:1630-1636,1990.
22. Grimm, E. A., Moser, R. P., Blacklock, J. B., Loudon, W. G., and Carinhas, J. Interleukin-2 and cytotoxic lymphocyte therapy of primary and metastatic brain tumors. In: B. B. Johansson, C. Owman, and H. Widner (eds.), Pathology Blood Brain Barrier, Amsterdam, the Netherlands: Elsevier Science Publishers, pp. 527-540.1990.
23. Yang, S. C., Owen-Schaub, L. B., Roth, J. A., and Grimm, E. A. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin-2 and tumor necrosis factor a. Cancer Res., 50:290-293,1990.
24. Yasumoto, K., Miyazaki, K., Nagashima, A., Ishida, T., Kuda, T., Yano, T., Sugimachi, K., and Nomoto, K. Induction of lymphokine-activated killer cells by intrapleural installations of recombinant interleukin 2 in patients with malignant pleurisy due to lung cancer. Cancer Res., 47: 2184-2187, 1987.
25. Urba, W. J., Clark, J. W., Steis, R. G., Bookman, M. A., Smith, J. W., II, Beckner, S., Maluish, A. E., Rossio, J. L., Rager, H., Ortaldo, J. R., and Longo, D. L. Intraperiotoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer immunologic considerations. J. Natl. Cancer Inst., 81:602-611,1989.
26. Stewart, J. A., Belinson, J. L., Moore, A. L., Dorighi, J. A., Grant, B. W., Haugh, L. D., Roberts, J. D., Albertini, R. J., and Branda, R. F. Phase I trial of intraperitoneal recombinant interleukin 2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res., 50:6302-6310, 1990.
27. Leist, T. P., Frei, K., Kam-Hansen, S., Zinkernagel, R. M., and Fontana, A. Tumor necrosis factor a in cerebrospinal fluid during bacterial, but not viral, meningitis. Evaluation in murine model infections and in patients. J. Exp. Med., 167:1743-1748, 1988.
28. Mustafa, M. M., Ramillo, O., Saez-Llorens, X., Olsen, K. D., Magness, R. R., and McCreacken, G. H., Jr. Cerebrospinal fluid prostaglandins, interleukin 1β, and tumor necrosis factor in bacterial meningitis. Clinical and laboratory correlations in placebo-treated and dexamethasone-treated patients. Am. J. Dis. Child, 144:883-887,1990.
29. Kovacs, E. J., Beckner, S. K., Longo, D. L., Varesio, L., and Young, H. A. Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 10 by interleukin 2. Cancer Res., 49:940-944,1989.
30. Smith, D. M., Lackides, G. A., and Epstein, L. B. Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity. Cancer Res., 50:3146-3153,1990.
31. McIntosh, J. K., Jablons, D. M., Mule, J. J., Nordan, R. P., Rudikoff, S., Lotze, M. T., and Rosenberg, S. A. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J. Immunol., 143:162-167,1989.
32. Jablons, D. M., Mule, J. J., McIntosh, J. K., Sehgal, P. B., May, L. T., Huang, C. M., Rosenberg, S. A., and Lotze, M. T. IL-6/IFN-0-2 as a circulating hormone. Induction by cytokine administration in humans. J. Immunol., 142:1642-1647,1989.
33. Fong, Y., and Lowry, S. F. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin. Immunol. Immunopathol., 55: 1557-1570,1990.
34. Scholz, W., McClurg, M. R., Cardenas, G. J., Smith, M., Noonan, D. J., Hugli, T. E., and Morgan, E. L. C5a-mediated release of interleukin 6 by human monocytes. Clin. Immunol. Immunopathol., 57: 297-307,1990.
35. Rubin, L. A., Kurman, C. C., Fritz, M. E., Biddison, W. E., Boutin, B., Yarchoan, R., and Nelson, D. L. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol., 135:3172-3177, 1985.
36. Ward, M. M., Russell, P. H., and Pisetzky, D. S. Serum Interleukin-2 receptor responses to immunization. Clin. Immunol. Immunopathol., 57: 120-124,1990.
37. Dinarello, C. A. The biology interleukin 1 and comparison to tumor necrosis factor. Immunol. Lett., 16:227-231,1987.
38. Kovacs, E. J., Beckner, S. K., Longo, D. L., Varesio, L., and Young, H. A. Cytokine gene expression during the generation of human lymphokine-activated killer cell activity. Early induction of interleukin 1/9 by interleukin 2. Cancer Res., 49:940-949,1989.
39. Rosenberg, S. A., Schwarz, S. L., and Spiess, P. J. Combination immuno-therapy for cancer: synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor-infiltrating lymphocytes. J. Natl. Cancer Inst., 80: 1393-1397,1988.
40. Phillips, J. H., Gemio, B. T., Myers, W. W., Rayner, A. A., and Lanier, L. L. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J. Clin. Oncol., 5: 1933-1941,1987.
41. Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., and Cerami, A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (Washington, DC), 232:911-919,1986.
42. Han, J., Thompson, P., and Beutler, B. Dexamethasol and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med., 172:391-394, 1990.
43. Ostensen, M. E., Thiele, D. L., and Lipsky, P. E. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2. J. Biol. Response Modifiers, 8:53-61,1989.
44. Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T., and Kishimoto, T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T-cells. J. Immunol., 141:1543-1549,1988.
45. Mule, J. J., McIntosh, J. K., Jablons, D. M., and Rosenberg, S. A. Antitumor activity of recombinant interleukin 6 in mice. J. Exp. Med., 171: 629-636, 1989.
46. Moser, R. P., Bruner, J., and Grimm, E. A. Biological therapy for brain tumors. Cancer Bull., 43:117-126, 1991.
47. Lieberman, A. P., Pitha, P. M., and Shin, M. L. Protein kinase regulates tumor necrosis factor mRNA stability in virus-stimulated astrocytes. J. Exp. Med., 172:989-992,1990.
48. Saris, S. C., Rosenberg, S. A., Friedman, R. B., Rubin, J. T., Barba, D., and Oldfield, E. H. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J. Neurosurg., 69:29-34, 1988.
49. Wesselingh, S. L., Gough, N. M., Finlay-Jones, J. J., and McDonald, P. J. Detection of cytokine mRNA in astrocyte cultures using the polymerase chain reaction. Lymphokine Res., 9:177-185,1990.
50. Ettinghausen, S. E., Puri, R. K., and Rosenberg, S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst, 80:177-188,1988.
51. Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol., 137:1735-1742,1986.
52. Alexander, J. T., Saris, S. C., and Oldfield, E. H. The effect of interleukin-2 on the blood-brain-barrier in the 9L gliosarcoma rat model. J. Neurosurg., 70:92-96, 1989.
53. Watts, R. G., Wright, J. L., Atkinson, L. L., and Merchant, R. E. histopathological and blood-brain-barrier changes in rats induced by an intracerebral injection of human recombinant interleukin 2. Neurosurgery, 25: 202-208, 1989.